Mark Litton has been appointed chief operating officer of Seattle-based Athira Pharma. Litton is the co-founder of Alder BioPharmaceuticals (NASDAQ: ALDR), and was chief business officer at that company until last July. Athira, previously known as M3 Biotechnology, is developing treatments for neurodegenerative disorders. The company is currently enrolling patients in a Phase 1b study testing lead drug NDX-1017 as a treatment for Alzheimer’s disease.
UNDERWRITERS AND PARTNERS
